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PANSAID—PAracetamol and NSAID in
combination: detailed statistical analysis
plan for a randomised, blinded, parallel,
four-group multicentre clinical trial
Kasper Højgaard Thybo1*, Janus Christian Jakobsen2, Daniel Hägi-Pedersen1, Niels Anker Pedersen3,
Jørgen Berg Dahl4, Henrik Morville Schrøder5, Hans Henrik Bülow6, Jan Gottfrid Bjørck7, Søren Overgaard8,9,
Ole Mathiesen10 and Jørn Wetterslev2
Abstract
Background: Effective postoperative pain management is essential for the rehabilitation of the surgical patient. The
PANSAID trial evaluates the analgesic effects and safety of the combination of paracetamol and ibuprofen. This
paper describes in detail the statistical analysis plan for the primary publication to prevent outcome reporting bias
and data-driven analysis results.
Methods/design: The PANSAID trial is a multicentre, randomised, controlled, parallel, four-group clinical trial comparing
the beneficial and harmful effects of different doses and combinations of paracetamol and ibuprofen in patients having
total hip arthroplastic surgery. Patients, caregivers, physicians, investigators, and statisticians are blinded to the
intervention. The two co-primary outcomes are 24-h consumption of morphine and proportion of patients with one or
more serious adverse events within 90 days after surgery. Secondary outcomes are pain scores during mobilisation and
at rest at 6 and 24 h postoperatively, and the proportion of patients with one or more adverse events within 24 h
postoperatively.
Discussion: PANSAID will provide a large trial with low risk of bias regarding benefits and harms of the combination
of paracetamol and ibuprofen used in a perioperative setting.
Trial registration: ClinicalTrials.org identifier: NCT02571361. Registered on 7 October 2015.
Keywords: Ibuprofen, Paracetamol, Total hip arthroplasty, Benefit, Harm, Multimodal analgesia, Postoperative pain,
Detailed statistical analysis plan, Randomised controlled trial
Background
Effective postoperative pain management is a core com-
ponent in enhanced recovery after surgery programs
and is essential for the rehabilitation of surgical patients
[1–3]. Patients are often treated with different combi-
nations of non-opioid drugs and analgesic methods
(“multimodal analgesia”) to achieve better analgesic ef-
fects and lower the requirement for opioids.
The literature on postoperative multimodal analgesia is
characterised by small studies using a variety of different
combinations of drugs, inconsistency in outcome report-
ing, and types of surgery with short follow-up [4, 5].
Consequently, the effects of most combinations of anal-
gesics are not well documented [4] and there is a sig-
nificant risk that patients’ pain will either be treated
insufficiently or that patients receive combinations of an-
algesics without additive effects but with an increased risk
of adverse effects [5].
The International Conference on Harmonisation (ICH)
of Good Clinical Practice (GCP) [6] and leading experts
recommend that randomised clinical trials should be
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analysed according to predefined outcomes and a pre-
defined detailed statistical analysis plan [7]. To pre-
vent outcome reporting bias and data-driven analysis
results and increase transparency this paper will in
detail describe the detailed statistical analysis plan for
the PANSAID trial [8] while enrolment of patients
and collection of data is still on-going and before the
database is accessed for trial results.
Methods/design
Trial overview
PANSAID is a multicentre, randomised, controlled, par-
allel, four-group clinical trial comparing the beneficial
and harmful effects of different doses and combinations
of paracetamol and ibuprofen in patients having total
hip arthroplasty (THA) surgery. Patients are randomised
to four groups in a 1:1:1:1 ratio (Fig. 1, Additional file 1).
The patients will receive one of the following treatments
for the first 24 h postoperatively: Treatment A) paraceta-
mol 1 g + ibuprofen 400 mg, four times; Treatment B)
paracetamol 1 g + placebo, four times; Treatment C) pla-
cebo + ibuprofen 400 mg, four times; Treatment D)
paracetamol 0.5 g + ibuprofen 200 mg, four times (Fig. 2).
The patients, caregivers, physicians, investigators, and
statisticians are blinded to the intervention. Conclusions
will be made blinded to the interventions. The patients
are enrolled in the trial only after obtaining informed
consent. The trial is conducted at six centres (Næstved,
Holbæk, and Nykøbing Falster Hospitals, Gildhøj Private
Hospital, Odense University Hospital, and Zealand Uni-
versity Hospital Køge). The aim of the PANSAID trial is
to investigate analgesic effects and safety of paracetamol
and ibuprofen and their combination in different dos-
ages after THA. The trial background, design, and ra-
tionale have previously been published [8].
The trial is registered at ClinicalTrials.org (NCT02571361)
and EudraCT (2015-002239-16) and conducted in ac-
cordance with the Helsinki Declaration and approved by
the Biomedical Research Ethics Committee of Region
Zealand (SJ-462), Danish Medicine Agency (EudraCT
2015-002239-16), and the Danish Data Protection Agency
(REG-33-2015). The progression of the trial can be moni-
tored at the homepage (www.PANSAID.dk).
This detailed statistical analysis plan has been written
while data collection from the PANSAID trial is on-
going. The data analysis of the main publication will
Fig. 1 CONSORT Flow-diagram
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follow this plan. The detailed statistical analysis plan was
approved by the PANSAID steering committee on 25
April 2017.
Sample size
The PANSAID trial has two primary outcomes: 1) 24-h
postoperative morphine consumption; and 2) proportion
of patients with one or more serious adverse events
(SAE) within 90 days after surgery. The sample size esti-
mation is based on 24-h morphine consumption. Due to
six possible comparisons and a wish to limit the family-
wise error rate to 0.05 (a 0.025 (two-sided) error rate for
each of the two primary outcomes), the type one error
rate is α = 0.0042 (two-sided). Based on power (1 – β) =
0.90, α = 0.0042, and standard deviation of 20 mg (un-
published data from our research team) we need to ran-
domise 139 individuals in each intervention group (556
in total) to detect a minimal clinically relevant difference
of 10 mg in 24-h morphine consumption. We expect the
largest difference between Group A (paracetamol 1 g +
ibuprofen 400 mg) and Group B (paracetamol 1 g +
placebo).
For the co-primary outcome of patients with one or
more SAE within 90 days of surgery, we will collate
events according to whether the patients used ibuprofen
corresponding to one comparison of 417 versus 139 pa-
tients. With a type one error rate of 0.025 (two-sided)
this renders a power of 80% to detect an increase in pa-
tients having one or more SAE within 90 days of surgery
from 10% to 21% if ibuprofen is used [9].
This sample size estimation has been made with the
power and sample size program PS [10] and is based on
the assumption that data on supplementary morphine con-
sumption will be normally distributed. This assumption
may not hold and we consider the possibility that a non-
parametric test will be necessary if normal distribution by
Log transformation is unobtainable. However, we do not
expect indefinite tails (very large standard deviations) in
the distribution of supplementary morphine consump-
tion and we have many more patients in our interven-
tion groups than required for using explicit sample size
calculations for the use of the Van Elteren test [11].
We do not expect that any patients will be lost to
follow-up. If the patient-controlled analgesia (PCA)-
morphine is discontinued we will convert additional
oral/intravenous opioid to morphine equivalent doses (at
this point we are missing two morphine values (2/482 =
0.4%)). Regarding the outcome of SAE, the Danish Na-
tional Patient Registry provides data on all citizens in
Denmark and therefore we will only have missing values
on the rate of SAE if participants leave Denmark (which
is very unlikely so soon after surgery).
Stratification and design variables
The only stratification variables used in the randomisa-
tion is site. All primary analyses will be adjusted for ‘site’.
We will secondly adjust analyses for age (continuous),
sex (male/ female), previous use of paracetamol (daily
use, as needed, or not), and previous use of non-
steroidal anti-inflammatory drugs (NSAIDs) (daily use,
as needed, or not). Results from the adjusted analyses
Fig. 2 SPIRIT figure: PANSAID
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will be briefly presented in the primary publication (in
the text, supplementary material, or as a forest-plot). In-
depth analyses of all the sub-groups (and the adjusted
analysis) will follow in subsequent publications. The
sub-groups have previously been defined [8] and can
been seen at the trial website.
Outcomes
Primary outcome
PANSAID has two co-primary outcomes:
 Total 24-h morphine consumption administered as:
1) PCA-morphine pump from end of surgery (2 mg/
dose; lockout 10 min); and 2) additional boluses
given the first hour after the end of surgery.
 Proportion of patients having one or more SAE
from end of surgery to 90 days postoperatively.
Serious adverse events are defined as SAE
(according to ICH-GCP guidelines) including death,
but except for ‘prolongation of hospitalisation’.
Secondary outcomes
 Pain scores (visual analogue scale (VAS), 0–100 mm)
at rest at 6 and 24 h postoperatively.
 Pain scores (VAS, 0–100 mm) during 30 degree
flexion of the hip at 6 and 24 h postoperatively.
 Proportion of patients with one or more adverse
events (AE) in the intervention period (the first 24 h
postoperatively).
Exploratory outcomes
 Level of nausea at 6 and 24 h postoperatively
(none, mild, moderate, severe).
 Number of vomiting episodes (0–24 h).
 Consumption of ondansetron (mg) in the period
0–24 h postoperatively.
 Level of sedation at 6 and 24 h postoperatively
(none, mild, moderate, severe).
 Level of dizziness at 6 and 24 h postoperatively
(none, mild, moderate, severe).
 Blood loss during the surgical procedure
(intraoperatively; ml).
 Days alive outside hospital within 90 days after
surgery.
Measurement of outcome variables
Local investigators and clinical staff at each hospital col-
lect outcome data in the intervention period (0 to 24 h
postoperative). The data are collected at 6 (± 1) and 24
(± 1) h postoperatively. Pain scores, nausea, vomiting,
dizziness, and sedation are reported by the patients.
Follow-up data are collected by interviewing the patient
(either by telephone or at the hospital if a 3-month
follow-up visit is scheduled by the surgeon), and by
registries (the Danish National Patient Registry for SAEs
and death).
The exact definitions of outcome variables are de-
scribed in the protocol article [8].
Baseline characteristics
The baseline characteristics of the participants will be
assessed after inclusion in the trial using data from the
time of scheduling the surgery to randomisation. The
baseline characteristics can be seen in Table 1.
General analyses principles and populations
The primary conclusion of the trial will be based on the
results from the primary analyses of the co-primary out-
comes. All analyses will be made on both a modified
intention-to-treat (mITT) population and a ‘strictly per
protocol’ (sPP) population. The mITT population will
include patients randomised and having the THA sur-
gery (excluding patient randomised, but afterwards can-
celled in the operating room). The sPP population will
exclude patients having one or more major protocol vio-
lations. Major protocol violations are defined as:
1. Patients that did not get any of the dosages of the
randomized allocated trial treatment, or
2. Patients withdrawing from the trial intervention
allowing the use of registered data, or
3. Patients undergoing additional surgery (besides the
elective THA) or a procedure in the intervention
period that requires anaesthesia or sedation and/or
analgesia
The sPP analyses regarding SAEs and other safety vari-
ables will, however, include patients with major protocol
violation definition number 3. Furthermore, the sPP
population will exclude patients who received any anal-
gesic medications in the intervention period other than
the study medication and PCA-morphine (e.g. paraceta-
mol, NSAIDs, intrathecal opioids, steroids, local infiltra-
tion analgesia, etc.). The evaluability of each patient for
the statistical analyses will be performed before the code
is broken.
If patients have received opioids other than PCA-
morphine in the intervention period these will be con-
verted to morphine equivalents (according to Appendix 2
in Hojer Karlsen et al. [12]) and added to the cumulated
dose of consumed PCA-morphine.
The trial is conducted at six sites. There are no fixed
sample size requirements for each site. We will merge
sites with fewer than 30 patients when entering the site
as a co-variable in the statistical models. We expect to
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merge the sites Holbæk and Nykøbing Falster Hospitals.
These two hospitals are similar with respect to size, pro-
portion of elective surgery compared with emergency
surgery, etc.
Level of significance
To maintain an overall family wise error rate of 0.05 the
level of significance for the co-primary outcome regarding
24-h morphine consumption has been set to 0.0042
(two-sided) after a Bonferroni adjustment due to two co-
primary outcomes and six possible comparisons and the
anticipation that the intervention effect estimated from
these comparisons do not correlate. The level of signifi-
cance for the co-primary outcome regarding SAE has
been set to 0.025 (two-sided) after a Bonferroni adjust-
ment due to two co-primary outcomes anticipated to be
independent. We have corrected the secondary outcomes
because of the six comparisons and the levels of signifi-
cance for the secondary outcomes are 0.0084 (two-sided).
Due to the hypothesis generating nature of the exploratory
outcomes these will not be corrected for multiple compar-
isons and the level of significance is 0.05 (two-sided).
Handling of missing data
If data are only missing on the dependent variable then
we will use the complete cases only. Otherwise, if there
are more than 5% missing data and Littles’s test is statis-
tically significant we will use multiple imputations (MI)
to impute missing data [13, 14]. Complete case analysis
will be performed as well but the results of the analyses
using MI imputed datasets will be considered the pri-
mary result of the trial.
Statistical analysis
Statistical analysis of the primary outcome
The primary analysis of the continuous outcome of mor-
phine consumption within 24 h will be pair-wise com-
parisons between the median consumption of morphine
between the four groups (six analyses) adjusted for sites
based on the mITT population. We will use Van Elterens
test [15] to stratify for site. We will use bootstrapping to
present 99.6% and 95% confidence intervals for the
mean difference.
The secondary analyses of the primary outcome of
morphine consumption are:
 An analysis adjusted for sites based on the sPP
population.
 An analysis using the generalized estimation
equations (GEE) [16] based on the mITT. This
analysis will be adjusted for ‘site’ and design
variables (age (continuous), sex (male/ female),
previous use of paracetamol (daily use, as needed,
or not), and previous use of NSAID (daily use, as
needed, or not).
Table 1 Baseline characteristics
Demographic characteristics: Age (years)
Sex (male/female)
American Society of Anaesthesiologist (ASA) physical status score
Height (cm)
Weight (kg)
Body mass index (BMI; kg/m2)
Prior use of analgesic medication
• Use of paracetamol: no use, daily use, or ‘as needed’
• Use of ibuprofen: no use, daily use, or ‘as needed’
• Use of tramadol: no use, daily use, or ‘as needed’
• Use of codeine: no use, daily use, or ‘as needed’
• Use of other non-steroidal anti-inflammatory drugs: no use, daily use, or
‘as needed’
Surgical characteristics: Duration of surgery (min)
Type of surgery
• Uncemented, cemented, or hybrid total hip arthroplasty
Type of anaesthesia
• General anaesthesia, spinal anaesthesia, conversion of spinal anaesthesia
to general anaesthesia, or spinal anaesthesia with sedation
○ If general anaesthesia: amount of sufentanil (μg) given 15 min before
‘end of surgery’
○ If spinal anaesthesia: amount of bupivacaine (mg) used
Thybo et al. Trials  (2017) 18:465 Page 5 of 7
If the outcome of morphine consumption is normally
distributed, or normally distributed when log-transferred,
we will use conventional parametric statistics. How-
ever, we expect the distribution of this outcome to be
non-normal.
The primary analysis of the proportion of patients with
one or more SAE in the trial period (within 90 days after
surgery) will be analysed using GEE with a log link func-
tion to obtain relative risks (RRs), combining the groups
receiving ibuprofen (417 patients) and comparing them
to patients not receiving ibuprofen (139 patients) using
the mITT population adjusted for site.
Secondary analyses of number of patients with one or
more SAE are:
 An analysis adjusted for ‘site’ based on the sPP
population
 GEE adjusted for ‘site’ and design variables based
on the mITT population.
As a sensitivity analysis of the outcome of SAE we
will perform an analysis excluding patients from Group
B (paracetamol + placebo) who took NSAIDs in the
follow-up period. This is not described in detail in the
protocol. However, our main objective is to investigate
whether the use of NSAIDs in the in-hospital period
(the intervention period) increases the numbers of SAE
despite patients using these drugs when discharged
from hospital.
We have chosen the GEE model because of its ability
to handle correlated data and few events per site. GEE is
a valid method that can be used both for analysis of lon-
gitudinal data as well as intra-centre correlations [17].
For all GEE models we will use model-based (non-ro-
bust) standard errors [16] and site will be entered as a
clustering variable.
Statistical analysis of the secondary outcomes
The primary analysis of the continuous data of pain
scores are analysed using GEE adjusted for ‘site’.
The primary analysis of the variable of the proportion
of patients having one or more AE in the intervention
period will be analysed using GEE with a log link func-
tion to obtain RRs adjusted for ‘site’.
Secondary analyses of the secondary outcomes are:
 Analyses adjusted for ‘site’ based on the sPP
population
 Analyses adjusted for ‘site’ and design variables
based on the mITT population using GEE for the
continuous data of pain scores and a GEE with a log
link function for the variable of patients having one
or more AE in the intervention period.
Statistical analysis of the exploratory outcomes
For the exploratory outcomes of nausea, dizziness, and
sedation, we will dichotomize data to none/mild versus
moderate/severe and analysed using GEE with a log link
function adjusted for ‘site’ to obtain RRs.
The continuous outcomes of consumption of ondanse-
tron, number of vomiting episodes, days alive and outside
hospital, and blood loss during the surgical procedure will
be analysed using the van Elteren test adjusted for ‘site’.
Secondary analyses of the exploratory outcomes are:
 Analyses adjusted for ‘site’ based on the sPP
population
Outline of figures and tables
The first figure will be a Consolidated Standards of
Reporting of Randomised Trials (CONSORT) flow chart.
The first table will be the baseline characteristics of the
mITT population. The second table will be of the two
co-primary outcomes (24-h morphine consumption and
number of patients with one or more SAE within
90 days) according to the four groups and pair-wise
comparisons. The third table will be the secondary and
exploratory outcomes.
Blinding of the statistician
Prior to breaking of the randomisation code an inde-
pendent statistician will perform the data analyses ac-
cording to this detailed statistical analysis plan. The
analyses of the SAE outcome will be between Group B
and all other groups combined. In order to maintain
blinding the statistician will perform the analyses of the
SAE outcome in four rounds assuming that one of the
groups is Group B.
Based on the masked result, the steering committee
will agree upon abstracts covering all possible combina-
tions and then the blinding will be broken [18]. The final
manuscript will contain the correct pre-written abstract.
Discussion
PANSAID will provide data from a large trial with over-
all low risk of bias regarding benefits and harms of the
combination of paracetamol and ibuprofen used in a
perioperative setting, which is urgently needed [19, 20].
The full, pseudo-anonymised data set will be made pub-
licly available 18 months after last follow-up of the last
randomised patient.
Trial status
At present, more than 500 patients have been en-
rolled in the trial and we expect to finish recruiting
in October 2017.
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